IL-33 is abundantly expressed in specific regions of the brain and spinal cord, mediates the interaction between immune, endothelial and CNS (central nervous system) resident cells and plays a key role in the development and homeostasis of the CNS. Astrocytes are the primary source of local IL-33 that stimulates synapse elimination by microglia during early CNS development (see FIGURE 1). Deletion of IL-33 in astrocytes leads to abnormal synaptic connections. IL-33 is involved in the neuroinflammation of many neurological diseases such as Alzheimer\u2019s disease (AD) and multiple sclerosis (MS).<\/p>\n\n\n\n
Different studies suggest that IL-33 is involved in the myelination process during CNS development and also likely the repair phase in demyelinating diseases such as MS and that IL-33 plays a critical role in the maintenance and repair of ageing and stressed neurons during AD.<\/p>\n\n\n\n The IL-33 (mouse), mAb (rec.) (blocking) (Bondy-1-1) (Prod. No. AG-27B-0013<\/a>) is a recombinant antibody developed and produced in-house at AdipoGen Life Sciences. It is produced without the use of animals and purified from HEK 293 cell culture supernatant. This unique antibody has functional activities and inhibits the binding of mouse IL-33 to ST2\/IL-1RAcP.<\/p>\n\n\n\n Figure:<\/strong> Binding of IL-33 (mouse) to ST2\/IL-1RAcP is inhibited by IL-33 (mouse), mAb (rec.) (blocking) (Bondy-1-1) (preservative free) (AG-27B-0013PF<\/a>).<\/p>\n\n\n\n Methods:<\/strong> IL-33 (mouse) was coated on an ELISA plate at 1\u03bcg\/ml. IL-33 (mouse), mAb (rec.) (blocking) (Bondy-1-1) (preservative free) (AG-27B-0013PF<\/a>) or an unrelated mAb (recombinant) (Control) were added (starting at 40\u03bcg\/ml with a twofold serial dilution) together with 100\u03bcl of supernatant of cells containing ST2 (human):Fc\/IL-1RAcP (human):Fc. After incubation for 1h at RT, the binding was detected using an anti-Fc human antibody (HRP).<\/p>\n<\/div> IL-33 (oxidation resistant) (human) (rec.) (untagged) (Prod. No. AG-40B-0160<\/a>) and IL-33 (oxidation resistant) (human) (rec.) (His) (Prod. No. AG-40B-0167<\/a>) are both specifically designed proteins. The biological activity of IL-33 at its receptor ST2 is rapidly terminated in the extracellular environment by its oxidation (formation of two disulfide bridges), resulting in an extensive conformational change that disrupts the ST2 binding site. Mutations at amino acids C208S\/C232S protect IL-33 from oxidation and increase its activity.<\/p>\n\n\n\n IL-33 (oxidation resistant) (human) (monomeric):Fc-KIH (human) (rec.) (Prod. No. AG-40B-0233<\/a>) is a new engineered Knobs-into-Holes construct, which allows the production of a monomeric protein, but at the same time creating stable and long-lasting Fc-KIH recombinant protein.<\/p>\n\n\n\n LIT:<\/strong> Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation: E.S. Cohen, et al.; Nat. Commun. 6,<\/strong> ID8327 (2015)<\/p>\n\n\n\n Figure:<\/strong> Activation in vivo of Innate Lymphoid Cells 2 (ILC2) by IL-33 (oxidation resistant) (human) (rec.) (untagged) (AG-40B-0160<\/a>).<\/p>\n\n\n\n Method:<\/strong> C57BL\/6 mice were injected daily for 3 days with PBS (Figure A) or IL-33 (oxidation resistant) (human) (rec.) (untagged) (AG-40B-0160<\/a>) (at 0.4\u00b5g per mouse) (Figure B). At day 4, cells from bone marrows were stained and analyzed by flow cytometry. Levels of ST2 and KLRG1 on Innate Lymphoid Cells (gated as lineage negative, CD127 positive cells) are shown. Picture courtesy of Dr G.Verdeil \/ Dr S. Trabanelli (Camilla Jandus Group, Department of Fundamental Oncology, University of Lausanne).<\/p>\n<\/div> AdipoGen Life Sciences’ HpARI (Alarmin Release Inhibitor) (rec.) (His) (Prod. No. AG-40B-0178<\/a>) and HpARI (CCP1\/2) (rec.) (Prod. No. AG-40B-0201<\/a>) (His) are recombinantly produced proteins. <\/p>\n\n\n\n HpARI is a protein normally secreted by the mouse parasite Heligmosomoides polygyrus<\/em>. The mature protein HpARI, containing three predicted Complement Control Protein (CCP)-like modules (also known as Short Consensus Repeats (SCRs) or sushi-domains), suppresses type 2 (allergic) immune responses through interference in the interleukin-33 (IL-33) pathway. During cell damage, HpARI gains access to the nucleus of necrotic cells, where it binds directly to IL-33 and nuclear DNA, preventing secretion and binding of IL-33 to its receptor. A non-natural truncation consisting of the first 2 domains of HpARI (CCP1\/2) retains IL-33 and DNA binding capacity. HpARI (CCP1\/2) is able to stabilise IL-33, increasing its half-life and amplifying its effects. HpARI (CCP1\/2) increases IL-33 activity by protecting it from oxidation and proteolytic degradation. HpARI (CCP1\/2) (rec.) (His) is a new type of reagent to study IL-33-mediated pathology in vivo. HpARI is a new type of reagent to prevent IL-33-mediated pathology.<\/p>\n\n\n\n LIT:<\/strong> HpARI protein secreted by a helminth parasite suppresses interleukin-33: M. Osbourne, et al.; Immunity 47,<\/strong> 739 (2017) | A Truncated Form of HpARI Stabilizes IL-33, Amplifying Responses to the Cytokine: C. Chauche, et al.; Front. Immunol. 11,<\/strong> 1363 (2020)<\/p>\n\n\n\n Figure:<\/strong> Binding of HpARI (CCP1\/2) (rec.) (His) (Prod. No. AG-40B-0201<\/a>) to human and mouse IL-33.<\/p>\n\n\n\n Method:<\/strong> IL-33 (human) (rec.) (untagged) (Prod. No. AG-40B-0038<\/a>), IL-33 (mouse) (rec.) (untagged) (Prod. No. AG-40B-0041<\/a>) as well as an unrelated protein as control are coated on an ELISA plate at 1\u00b5g\/ml. After blocking and washing steps, indicated concentrations of HpARI (CCP1\/2) (rec.) (His) is added. Following incubation for 1h at RT, the binding is detected using an anti-His antibody (HRP).<\/p>\n<\/div> AdipoGen Life Sciences’ anti-ST2 (human), pAb (Prod. No. AG-25A-0058<\/a>) is a polyclonal antibody that recognizes soluble human ST2 in Western blot and Flow Cytometry. Soluble ST2 plays a role in protecting ILC2 from IL-33 stimulation and thereby maintaining them in a na\u00efve state and it might be important for the regulation of several diseases. This antibody is available unlabelled and as labelled versions with ATTO 448 (Prod. No. AG-25A-0058YTD<\/a>) and ATTO 647N (Prod. No. AG-25A-0058YTS<\/a>).<\/p>\n\n\n\n Figure:<\/strong> Detection of endogenous human ST2 with anti-ST2 (human), pAb (ATTO 488) (AG-25A-0058YTD<\/a>).<\/p>\n\n\n\n Method:<\/strong> Total PBMCs (Peripheral Blood Mononuclear Cells) were stained with anti-ST2 (human), pAb (ATTO 488) (1:100 in PBS + 2% FCS) (Figure B) or with no antibody (Figure A) for 1h at 4\u00b0C. The staining was analysed by flow cytometry.<\/p>\n<\/div>![\"\"](\"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-172.png\")
<\/a>AdipoGen Life Sciences offers a broad range of unique and potent IL-33 research tools:<\/h3>\n\n\n\n
\n
Literature References:<\/h4>\n\n\n\n
\n
Most Comprehensive & Unique IL-33 Reagents for Type 2 Immune Response Research<\/h2>\n\n\n\n
UNIQUE IL-33 Blocking Antibody<\/h3>\n\n\n\n
<\/figure><\/div>\n\n\n\nHighly Active Human IL-33 Proteins – Oxidation Resistant<\/h3>\n\n\n\n
<\/figure><\/div>\n\n\n\nUNIQUE HpARI – Suppressor of Type 2 (Allergic) Immune Response <\/h3>\n\n\n\n
<\/figure><\/div>\n\n\n\nPOTENT ST2-specific Antibody for Flow Cytometry <\/h3>\n\n\n\n
<\/figure><\/div>\n\n\n\nAll Recombinant IL-33 Proteins & Related Proteins <\/h3>\n\n\n\n
Product Name<\/th> Product Code<\/th> Product Description<\/th><\/tr><\/thead> HpARI (Alarmin Release Inhibitor) (rec.) (His)<\/td> AG-40B-0178<\/a><\/td> Binds to human and mouse IL-33.<\/td><\/tr> HpARI (CCP1\/2) (rec.) (His)<\/td> AG-40B-0201<\/a><\/td> Binds to human and mouse IL-33.<\/td><\/tr> IL-33 (oxidation resistant) (human) (monomeric):Fc-KIH (human) (rec.)<\/td> AG-40B-0233<\/a><\/td> Activation in vivo of Innate Lymphoid Cells 2 (ILC2)<\/td><\/tr> IL-33 (oxidation resistant) (human) (rec.) (His)<\/td> AG-40B-0167<\/a><\/td> Activation in vivo of Innate Lymphoid Cells 2 (ILC2)<\/td><\/tr> IL-33 (oxidation resistant) (human) (rec.) (untagged)<\/td> AG-40B-0160<\/a><\/td> Activation in vivo of Innate Lymphoid Cells 2 (ILC2)<\/td><\/tr> IL-33 (human) (rec.) (untagged)<\/td> AG-40B-0038<\/a><\/td> Activates human and mouse ST2-dependent NF-\u03baB pathway.<\/td><\/tr> IL-33 (human) (rec.) (His)<\/td> AG-40A-0042<\/a><\/td> Activates human ST2-dependent NF-\u03baB pathway.<\/td><\/tr> IL-33 (mouse) (rec.) (untagged)<\/td> AG-40B-0041<\/a><\/td> Activates mouse and human ST2-dependent NF-\u03baB pathway.<\/td><\/tr> IL-33 (mouse) (rec.) (His)<\/td> AG-40A-0053<\/a><\/td> Activates mouse and human ST2-dependent NF-\u03baB pathway.<\/td><\/tr> ST2 (human):Fc (human) (rec.)<\/td> AG-40A-0059<\/a><\/td> Interacts with human IL-33.<\/td><\/tr> IL-33R [ST2] (mouse):Fc (mouse) (rec.)<\/td> CHI-MR-11033R<\/a><\/td> Measured by its ability to bind recombinant human IL-33 in a functional ELISA.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n All Recombinant IL-33 Related Antibodies<\/h3>\n\n\n\n
Product Name<\/th> Product Code<\/th> Product Description<\/th><\/tr><\/thead> anti-IL-33, mAb (IL33026B)<\/td> AG-20A-0043<\/a><\/td> Recognises human and mouse IL-33 in Immunoprecipitation and Western blot.<\/td><\/tr> anti-IL-33, mAb (IL33068A)<\/td> AG-20A-0042<\/a><\/td> Recognises human IL-33 in Western blot.<\/td><\/tr> anti-IL-33 (mouse), mAb (rec.) (blocking) (Bondy-1-1)<\/td> AG-27B-0013<\/a><\/td> Recognises mouse IL-33 in ELISA and Functional Application (Blocking).<\/td><\/tr> anti-IL-33 (mouse), mAb (rec.) (blocking) (Bondy-1-1) (preservative free)<\/td> AG-27B-0013PF<\/a><\/td> Recognises mouse IL-33 in ELISA and Functional Application (Blocking).<\/td><\/tr> anti-IL-33 (human), mAb (IL33305B)<\/td> AG-20A-0041<\/a><\/td> Recognises human IL-33 in Functional, Immunohistochemistry, Immunoprecipitation and Western blot.<\/td><\/tr> anti-IL-33 (human), pAb<\/td> AG-25A-0045<\/a><\/td> Recognises recombinant human IL-33 in Immunohistochemistry and Western blot.<\/td><\/tr> anti-IL-33 (mouse), pAb<\/td> AG-25A-0047<\/a><\/td> Recognises mouse IL-33 in Western blot.<\/td><\/tr> anti-IL-33 (mouse), mAb (rec.) (Carly-1-4)<\/td> AG-27B-0012<\/a><\/td> Recognises mouse IL-33 in Western blot.<\/td><\/tr> anti-ST2 (human), mAb (ST33868)<\/td> AG-20A-0044<\/a><\/td> Recognises human ST2 in Immunohistochemistry and Western blot.<\/td><\/tr> anti-ST2 (human), pAb<\/td> AG-25A-0058<\/a><\/td> Recognises soluble human ST2 in ELISA, Flow Cytometry and Western blot.<\/td><\/tr> anti-ST2 (human), pAb (ATTO 488)<\/td> AG-25A-0058YTD<\/a><\/td> Recognises soluble human ST2 in ELISA, Flow Cytometry and Western blot.<\/td><\/tr> anti-ST2 (human), pAb (ATTO 647N)<\/td> AG-25A-0058YTS<\/a><\/td> Recognises soluble human ST2 in ELISA, Flow Cytometry and Western blot.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n